Ascentage Pharma Group International · HKEX:6855
Ascentage Pharma Group International — Investor Presentation (November 2026)
45 slides from Ascentage Pharma Group International's investor presentation, Nov 16, 2026
Slide 1: Ascentage Company Overview November 2026
Ascentage Company Overview November 2026 6855 AAPG ®
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation has been prepared by Ascentage Pharma Group International (the "Company") and includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of
Slide 3: Major Hematology Malignancies: Patients first, science-based
3 CML ALL CLL MDS AML DLBCL/ TCL Major Hematology Malignancies Addressing unmet medical needs. Patients first. Innovation-driven. Science-based. Building a leading, integrated global biopharmaceutical company.
Slide 4: Ascentage at a Glance
Ascentage at a Glance Olverembatinib BCR-ABL Inhibitor Lisaftoclax Bcl-2 Selective Inhibitor 6855 HKEX IPO completed in October 2019 AAPG 2026 6/30 cash balance: $279.4m Nasdaq IPO completed in January 2025 10+ Indications 7 Novel Active Clin. Compounds 30+ INDs cleared 40+ Clinical Trials Dual list
Slide 5: Ascentage Evolved From Scientific Roots Into a Global Commercial-Stage Company
Ascentage Evolved From Its Scientific Roots Into a Global, Commercial-Stage Hematology- Oncology Company Sources: Company data; Muchmore SW et al., Nature 1996 (BCL-XL structure); Petros AM et al., PNAS 2001 (Bcl-2 structure); FDA approval of venetoclax (April 2016); NMPA approvals of Olverembatinib
Slide 6: A Global, Commercial-Stage Hematology Oncology Platform With Multiple Paths to Value
6 Ascentage: A Global, Commercial-Stage Hematology Oncology Platform With Multiple Paths to Value Creation Differentiated Commercial Portfolio • Olverembatinib: BIC potential 3G BCR::ABL1 TKI with activity across T315I-mutant and resistant CML • Lisaftoclax: BIC potential, next-gen, Bcl-2 inhibitor
Slide 7: Commercial-Stage Portfolio, Multiple Global Registrational Programs, and Deep Pipeline
Commercial-Stage Portfolio, Multiple Global Registrational Programs, and Deep Pipeline Asset Indication Clinical Program Phase 1 Phase 2 Phase 3 Lisaftoclax1 Selective Bcl-2 Inhibitor 1L HR-MDS + azacitidine (AZA) GLORA-4 Global registrational trial CLL/SLL with suboptimal BTKi response + BTK inhibi
Slide 8: Lisaftoclax Bcl-2 Selective Inhibitor
8 Lisaftoclax Bcl-2 Selective Inhibitor
Slide 9: Bcl-2: A Critical Cancer Target With Decades of Drug-Development History
Bcl-2: A Critical Cancer Target With Decades of Drug-Development History Ascentage's pioneering development efforts culminated in the first new selective Bcl-2 inhibitor approval in nine years Structure & Function Bcl-2 Overview Regulates mitochondrial permeability and programmed cell death ■ BH3-bi
Slide 10: Lisaftoclax: Advancing in Multiple Phase III Registrational Trials
Program Indication Phase 1 Phase 2 Phase 3 Marketed Pivotal Ph-II CLL/SLL1 GLORA-4 First-Line HR-MDS GLORA CLL/SLL sub-optimal BTKi response (Add-on) GLORA-2 First-Line CLL/SLL GLORA-3 First-Line Elderly and Unfit AML 1. In July 2025, Lisaftoclax was approved by NMPA in China for the treatment of ad
Slide 11: Lisaftoclax Rapid 5-Day Dose Ramp-Up and No Prior Lead-In
11 Dose ramp-up phase Day 1-5 20mg 50mg 100mg 200mg 400mg Target Dose Maintenance Therapy 600mg Once Daily Day 6 & Onwards Directly introduce the combination drug C1D1 D2--D7 C1D8 Achieves target dose in just 5 days Venetoclax 5-week dose ramp-up 20mg 50mg 100mg 200mg 400mg Week 1 Week 2 Week 3 Week
Slide 12: HR-MDS Patients Continue to Face Inadequate CR and OS Outcomes
Despite AZA and ven-based treatment approaches, HR-MDS patients continue to face inadequate CR and OS outcomes HR-MDS Patients Have Seen No New Approved Frontline Therapy in Over 20 Years AZA remains standard of care, with VERONA (addition of Venetoclax), failing to improve CR or OS Complete Respons
Slide 13: GLORA-4: Designed to Overcome VERONA's Toxicity in HR-MDS
GLORA-4: Designed to Overcome VERONA's Toxicity in HR-MDS VERONA failed due to toxicity ~2× higher AZA dose reductions with Ven + AZA Toxicity is critical in HR-MDS Added myelosuppression limits time on therapy Lisaftoclax: Designed for tolerability Differentiated pharmacology designed to avoid VERO
Slide 14: GLORA-4 Is Designed to Establish Lisaftoclax in Frontline HR-MDS
14 GLORA-4 Is Designed to Establish Lisaftoclax in Frontline HR-MDS Global Randomized Phase III Evaluating Lisaftoclax + AZA In Frontline HR-MDS Source: Company data. Key Takeaways Trial Design Double-blind, randomized, placebo-controlled; same AZA backbone in both arms HR-MDS Treatment-naive higher
Slide 15: Lisaftoclax: Backbone Targeted Therapy for AML, Including Venetoclax-Resistant
Lisaftoclax is a potential backbone targeted therapy addressing AML broadly, including Venetoclax-resistant AML Patients Need More Effective Options Across Frontline and Relapsed Disease Bcl-2 inhibition is established in frontline AML, but patients progressing after venetoclax have limited effectiv
Slide 16: Lisaftoclax Has Multiple Paths to Expand Across the AML Treatment Paradigm
Lisaftoclax Has Multiple Paths to Expand Across the Evolving AML Treatment Paradigm 16 GLORA-3 anchors the frontline opportunity, with potential in additional settings Sources: Fathi AT, et al. N Engl J Med 2026;395:845-58 (PARADIGM, NCT04801797); Kadia T, et al. ASH 2025 (APG2575AU101). Notes: PARA
Slide 17: Single Agent Deep/Durable Response in BTKi Failed R/R CLL/SLL
17 Single Agent Deep/Durable Response in BTKi failed R/R CLL/SLL ASH 2025 Abstract. Zhou K, et al. Lisaftoclax monotherapy for BTKi-failed R/R CLL/SLL (APG2575CC201)[P]. 67th ASH Annu Meet, 2025. NCT05147467. Company data cutoff as of July 25, 2025 Efficacy Assessment ORR 62.5% (45/72) MRD in PB ass
Slide 18: Strong Clinical Activity in AML and MDS, Including Venetoclax Failed AML
Potential to overcome Venetoclax resistance in AML and HR-MDS 103 patients were treated with Lisaftoclax (200/400/600/800 mg) combined with AZA Strong Clinical Activity in AML and MDS, Including Venetoclax Failed AML 18 ASH 2025 Abstract. Kadia T, et al. Lisaftoclax + azacitidine for myeloid maligna
Slide 19: Lower Rates of SAE and Infection, No AE-Related Deaths
▪ 2 deaths attributed to TRAE in Sonrotoclax study due to infectious pneumonia ▪ No deaths reported in Lisaftoclax study From Prescribing Information for Lisaftoclax, Sonrotoclax and Venetoclax 10.4% 11.7% 3.9% 36.2% 18.8% 10.1% 26.0% 31.0% 19.0% Infectious Pneumonia Upper Respiratory Infection ≥Gra
Slide 20: Lisaftoclax PK and Drug-Interaction Advantages vs Venetoclax and Sonrotoclax
AUC Lisaftoclax Venetoclax Sonrotoclax 2.4x 11x 7.9x ▪ Strong CYP3A inhibitors contraindicated with Venetoclax and Sonrotoclax ▪ Lisaftoclax shows minimal fluctuation in plasma concentration when combined with strong CYP3A4 inhibitors CLL/SLL patients are often elderly and immunocompromised, with fr
Slide 21: Lisaftoclax: Next-Generation Selective Bcl-2 Inhibitor
Lisaftoclax: Next-Generation Selective Bcl-2 Inhibitor Purpose-designed for potent Bcl-2 inhibition, shorter exposure, and treatment convenience Lisaftoclax Compared to Venetoclax 1 Efficacious in BTK-resistant WM PDX model in which Venetoclax shows no effect 2 Daily ramp-up vs. weekly ramp-up 3 Ext
Slide 22: Lisaftoclax: Cornerstone Asset Poised for Proprietary Combo Strategy
22 Lisaftoclax: Cornerstone Asset Poised for Proprietary Combo Strategy Across Multiple Hematologic Malignancies Portfolio assets across BCR::ABL1, MDM2-p53 and BTK provide multiple potential combination partners Lisaftoclax Olverembatinib 3G BCR::ABL1 inhibitor CML Ph+ ALL AML MDS Ph-neg. ALL APG-3
Slide 23: Olverembatinib (HQP1351) 3rd Generation BCR-ABL TKI
23 Olverembatinib (HQP1351) 3rd Generation BCR-ABL TKI
Slide 24: Olverembatinib in Global Phase III Registrational Trials
24 Olverembatinib in Global Phase III Registrational Trials Clinical Program Indications Phase 1 Phase 2 Phase 3 Marketed Pivotal Ph-II CML-CP with/without T315I Mutation; CML-AP with T315I Mutation1, 2 POLARIS-2 CML POLARIS-1 First-line Ph+ ALL POLARIS-3 SDH-deficient GIST Single-agent Marketed in
Slide 25: Key Shortcomings Remain with Current TKIs for CML
Key Shortcomings Remain with Current TKIs for CML 25 Despite therapeutic advances, efficacy, resistance and tolerability challenges persist across treatment classes Current CML Treatment Landscape Persistent Unmet Needs Transformed CML into a manageable chronic disease 1G TKI Imatinib Improved MMR v
Slide 26: Olverembatinib: 3G BCR::ABL1 Inhibitor With Full Mutation Coverage
Olverembatinib: 3G BCR::ABL1 Inhibitor With Full Mutation Coverage Designed to address resistance with broad mutational-coverage and long-term tolerability issues of existing TKIs ✗2G TKIs do not address the T315I mutation ✓Active across broad BCR::ABL1 mutation spectrum, including T315I and compoun
Slide 27: CML Therapies Moving Earlier, Raising the Bar for Post-1L Differentiation
Safety / efficacy profile, generic Imatinib, drive frontline selection Imatinib Dasatinib Nilotinib Bosutinib CML Therapies Are Moving Earlier, Raising the Bar for Post-1L Differentiation 27 As a differentiated 3G TKI with mature clinical evidence, Olverembatinib is poised to emerge as a leader in p
Slide 28: Olverembatinib Positioned to Address a Meaningful 2L+ CML Opportunity
• Activity across T315I, multi-TKI resistance, post-ponatinib, post-asciminib and heavily pretreated patients • Proven durability demonstrated by post- approval real-world evidence • Global registrational strategy supported by mature China experience Olverembatinib Positioned to Address a Meaningful
Slide 29: Olverembatinib Shows Potential as a Second-Line Treatment in CML-CP
Olverembatinib Shows Potential as a Second-Line Treatment in CML-CP 29 2026 ASCO. Li W, Zhang Y, Zhu H, et al. Updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML). Data cutoff: January 14, 2026. CCyR, complet
Slide 30: Phase 1b Study in Heavily Pretreated CML-CP Patients (U.S.)
Sources: JAMA Oncology. Jabbour E, Oehler VG, Koller PB, et al. Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. JAMA Oncol. 2025;11(1):28–35 1. Elias Jabbour et al. ESH-iCMLf 26th Annual John Goldman Conference on Ch
Slide 31: Olverembatinib Has Proven, Broad-Spectrum Coverage
Sources: IC50 heatmap: company data (BaF3 anti-proliferation assay; mean ± SD). Post-ponatinib and post-asciminib activity: Jabbour E, et al. JAMA Oncol 2025. 1. Includes M244V, F359V/I/C, A337T, G463D or P465S mutations. Olverembatinib Has Proven, Broad-Spectrum Coverage 31 Mutated region BaF3 muta
Slide 32: POLARIS-2 Design: Olverembatinib in CML-CP, Including T315I Mutations
Sources: Company data (POLARIS-2 trial design). POLARIS-2 Design: Olverembatinib in CML-CP, Including T315I Mutations Randomized comparison against bosutinib after ≥2 prior TKIs, with a single-arm T315I cohort; primary endpoint of MMR at 24 weeks in both parts PART A Randomized vs bosutinib Post-≥2
Slide 33: Registrational Phase II Study Demonstrates Durable Benefit With 4-Year Follow-Up
Sources: ASH 2025 Abstract. Jiang Q, et al. Olverembatinib for TKI-resistant CML-CP: 4-yr follow-up (Phase 2)[P]. 67th ASH Annu Meet, 2025. Poster No.: 3788. NCT04126681 Company data as of Jan 13, 2025. 33 • Significantly longer EFS and better tolerability than BAT arm • Majority of patients include
Slide 34: POLARIS-1 Part Demonstrates Deep Responses in Frontline Ph+ ALL
POLARIS-1 Part 1 Demonstrates Deep Responses in Frontline Ph+ ALL 34 ASH 2025 Abstract. Chen S, et al. Olverembatinib + low-intensity chemo for ND Ph+ ALL (POLARIS-1)[P]. 67th ASH Annu Meet, 2025. Poster No.: 1574. NCT06051409. Company data as of July 18, 2025 1. BCR-ABL/ABL1 ≤ 0.01% by qPCR Primary
Slide 35: Olverembatinib + Blinatumomab: Clinical Strategy in CML-LBP and Ph+ BCP-ALL
Olverembatinib + Blinatumomab: Clinical Strategy in CML-LBP and Ph+ BCP-ALL 35 Primary endpoints • Safety and tolerability • Efficacy Maintenance phase Olverembatinib (30 or 40 mg QOD) Cycle 1: DLT observation period *If 0/3 patients develop DLT, the dose escalates from 30 to 40 mg QOD. Olverembatin
Slide 36: Olverembatinib: Highly Competitive Among Emerging Therapies for CML / Ph+ ALL
Sources: Olverembatinib: JAMA Oncol. 2025;11(1):28–35 (U.S. Phase 1b, N=62); switch study EHA 2026 (EHA-4595 / PS1728, Wen B, N=105), a prospective, multicenter, controlled trial. 1. ELVN-001: newly MMR achieved by Week 24 in post-asciminib patients with 3–4 prior TKIs (28%, n=22) and 5+ prior TKIs
Slide 37: Clinical Pipeline
37 Clinical Pipeline
Slide 38: APG-3288: Differentiated BTK Degrader Designed to Address Resistance
38 APG-3288: Differentiated BTK Degrader Designed to Address Resistance Across B-Cell Malignancies Lead clinical candidate from proprietary protein degrader platform; global Phase 1 dose escalation underway Source: Company data. Degrades BTK to address both kinase and scaffolding functions Broad Mut
Slide 39: Alrizomadlin (APG-115): Small Molecule Inhibitor Targeting MDM2-p53
Alrizomadlin (APG-115): Orally Bioavailable, Highly Selective, Small Molecule Inhibitor Targeting MDM2-p53 Mechanism of Action Reactivates wild-type p53 by inhibiting MDM2-mediated suppression APG-115 Overview 6 FDA Orphan Drug Designations 2 FDA Rare Pediatric Disease Designations • China's Starlig
Slide 40: Alrizomadlin Alone or With Lisaftoclax in Pediatric RMS or STSs
40 2026 ASCO. Zhang YZ, Zhang Y, Lu SY, et al. Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for pediatric relapsed/metastatic rhabdomyosarcoma (RMS) and other soft-tissue sarcomas (STSs) Data cutoff: April 16, 2026. Efficacy of Alrizomadlin + Lisaftoclax in patients wit
Slide 41: Olverembatinib + Lisaftoclax in Pediatric R/R Ph+ ALL
41 Source: EHA 2026 Abstract. Zhang J, Wang J, Liu T, et al. Safety and preliminary efficacy of olverembatinib (HQP1351) combined with lisaftoclax (APG-2575) in pediatric patients with relapsed/refractory (R/R) Ph+ ALL. *Updated results to be presented at ASH 2026 (Poster #1547). Efficacy, PK, and S
Slide 42: Multiple Upcoming Catalysts
Multiple Upcoming Catalysts Lisaftoclax Bcl-2 inhibitor Olverembatinib BCR::ABL1 inhibitor APG-3288 GLORA-4 1L HR-MDS Topline readout anticipated 2H 27 GLORA-3 1L Unfit AML Enrollment completion anticipated YE 26 / 1Q 27 POLARIS-2 ≥2 TKIs CML-CP Enrollment completion anticipated 1H 27 POLARIS-1 1L P
Slide 43: Experienced Leadership Team and Board of Directors
Experienced Leadership Team and Board of Directors 43 MANAGEMENT TEAM Dajun Yang, M.D., Ph.D. Co-Founder | Chairman & CEO Yifan Zhai, M.D., Ph.D. Chief Medical Officer Jim Ziegler Chief Commercial Officer Faiçal Miyara, Ph.D. Chief Business Officer Veet Misra, Ph.D. Chief Financial Officer BOARD OF
Slide 44: World-Class Clinical Advisory Board
World-Class Clinical Advisory Board Allen S. Lichter, M.D. Dean of the University of Michigan Medical School Former CEO of ASCO Director of Radiation Therapy of NCI Paul A. Bunn Jr., M.D. Distinguished Professor at University of Colorado School of Medicine Arul Chinnaiyan, M.D., Ph.D. Howard Hughes
Slide 45: Patient-Centric Innovation; Global Breakthrough Therapies
Patient-Centric Innovation; Global Breakthrough Therapies APG-3288 Pelcitoclax (APG-1252) APG-2449 Alrizomadlin (APG-115) APG-5918 Olverembatinib Lisaftoclax ALL CLL AML DLBCL /TCL Major Hematology Malignancy MM MDS CML Headquarters: Cayman Islands 700 King Farm Blvd. Rockville, MD 20850 USA 133 Cas
Ascentage Pharma Group International — Investor Presentation (November 2026) on 6ix